Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease.
DOI:
https://doi.org/10.31053/1853.0605.v80.n4.42272Keywords:
diabetes mellitus type 2, cardiovascular diseases, hypoglycemic agents, sodium-glucose cotransporter 2 inhibitors, liraglutideAbstract
Objective: To estimate the proportion of individuals with established Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Disease (CVD) who are receiving pharmacological anti-diabetic treatment with evidence of cardiovascular benefit at a hospital in Argentina.
Materials and Methods: Cross-sectional study conducted at the Italian Hospital of Buenos Aires. A consecutive sample of adult patients affiliated with the institutional prepaid health plan active in March 2020, diagnosed with T2DM and established CVD, was included. Data were collected from the Electronic Health Record. The proportion of pharmacological adequacy (combined use of metformin plus sodium-glucose co-transporter 2 inhibitors and/or glucagon-like peptide 1 receptor agonists) was reported along with its respective 95% confidence interval (CI).
Results: A total of 1539 patients were included, with a mean age of 76.2 years; 65.3% were male, and 81.6% were overweight or obese. Hemoglobin A1c levels were recorded in the past year for 74.9% of patients, with an average value of 6.9% (SD 1.2). The most prescribed drugs were metformin (61.3%), insulin (26.7%), and gliptins (11%). Out of the total included patients, 82 exhibited pharmacotherapeutic adequacy for diabetes treatment, with a prevalence of 5.3% (95% CI 4.2-6.5).
Conclusions: The prevalence of prescribing anti-diabetic drugs with evidence of cardiovascular benefit was 5.3% (95% CI 4.2-6.5). This real-world evidence highlights the low frequency of prescribing this type of medication at the time of the study in a high cardiovascular risk population.
Downloads
References
Ministerio de Salud de la Nación. Guía de Práctica Clínica Nacional sobre Prevención, Diagnóstico y Tratamiento de la Diabetes Mellitus tipo 2, 2019. Buenos Aires, Argentina. Disponible en: https://bancos.salud.gob.ar/sites/default/files/2020-09/guia-nacional-practica-clinica-diabetes-mellitius-tipo2_2019.pdf
Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021.
Pan American Health Organization. Panorama of Diabetes in the Americas. Washington, DC: PAHO; 2022.
INDEC. Instituto Nacional de Estadística y Censos. "4° Encuesta Nacional de Factores de Riesgo. Resultados definitivos." (2019).
American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S144-S174. doi: 10.2337/dc22-S010. Erratum in: Diabetes Care. 2022 Mar 07;: Erratum in: Diabetes Care. 2022 Sep 1;45(9):2178-2181.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020 Dec 1;41(45):4317.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83. doi: 10.1186/s12933-018-0728-6.
Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 Feb;63(2):221-228. doi: 10.1007/s00125-019-05039-w. Erratum in: Diabetologia. 2020 Aug;63(8):1667.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
World Health Organization. "Diagnosis and management of type 2 diabetes (HEARTS-D)." World Health Organization: Geneva, Switzerland (2020).
Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022 Mar;145(9):e722-e759. doi: 10.1161/CIR.0000000000001040. Epub 2022 Jan 10.
Norrbacka K, Sicras-Mainar A, Lebrec J, Artime E, Díaz S, Tofé-Povedano S, et al. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain. Diabetes Ther. 2021 May;12(5):1535-1551. doi: 10.1007/s13300-021-01039-5. Epub 2021 Apr 16.
Dieuzeide G, Waitman J, Pugnaloni Rodríguez NS, Rodríguez MV, Nardone L, Oviedo A; Grupo de Investigadores de Argentina del Estudio CAPTURE. Estudio CAPTURE: Resultados argentinos sobre prevalencia de enfermedad cardiovascular en diabetes mellitus tipo 2 [CAPTURE Study: Argentine results on prevalence of cardiovascular disease in type 2 diabetes mellitus]. Medicina (B Aires). 2022;82(3):398-407. Spanish.
Hamid A, Vaduganathan M, Oshunbade AA, Ayyalasomayajula KK, Kalogeropoulos AP, Lien LF, et al. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. J Cardiovasc Pharmacol. 2020 Sep;76(3):313-320. doi: 10.1097/FJC.0000000000000864.
Forte, E. H., Buso, C. J., Duczynski, P., Cobo, A. L., Harwicz, P., Giorgi, M., Sanabria, H. Características clínicas y control cardiometabólico de personas con diabetes en el consultorio de cardiología en la República Argentina. Revista argentina de cardiología, (2020) Nov. 88(6), 517-524. doi: 10.7775/rac.es.v88.i6.18201.
Avilés-Santa ML, Monroig-Rivera A, Soto-Soto A, Lindberg NM. Current State of Diabetes Mellitus Prevalence, Awareness, Treatment, and Control in Latin America: Challenges and Innovative Solutions to Improve Health Outcomes Across the Continent. Curr Diab Rep. 2020 Oct 10;20(11):62. doi: 10.1007/s11892-020-01341-9.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
